Facial atrophy in HIV-related fat redistribution syndrome: anatomic evaluation and surgical reconstruction.
The use of highly active antiretroviral therapy (HAART) with protease inhibitors can result in a syndrome of peripheral wasting, facial fat atrophy, and central adiposity in as many as 64% of patients infected with human immunodeficiency virus (HIV) who are treated with this regimen for 1 year. In this study the authors evaluated 9 consecutive patients who presented with this disease to define further its anatomic features and to explore techniques for surgical correction. Three of these patients presented with severe facial atrophy, and underwent surgical exploration and reconstruction with submalar silicone implants. Two patients required additional soft-tissue augmentation with synthetic fillers and/or autologous fat. Outcomes were determined through clinical impressions of the patient and surgeons, and comparison of pre- and postoperative photographs. No extrusion or infection was encountered, although 1 patient required repositioning on one side. Both surgeons and patients were satisfied with the results at the long-term follow-up. Detailed anatomic evaluation revealed the presence of a fat pad of Bichat in all patients. Facial atrophy in HIV-related fat redistribution syndrome (HARS) is secondary to atrophy of the subcutaneous fat, but not of the deeper fat pads, as has been described. Durable surgical reconstruction is achieved with a combination of submalar silicone implantation and augmentation of the nasolabial fold. HARS causes noticeable disfigurement that stigmatizes the HIV-infected patient. Given the overall benefit of decreased morbidity and prolonged survival associated with HAART therapy, it is beneficial to attempt surgical correction of these debilitating sequelae before discontinuation of these drugs.
Talmor
Mia
M
Division of Plastic Surgery, Department of Surgery, New York Presbyterian Hospital, New York, NY 10021, USA.
Hoffman
Lloyd A
LA
LaTrenta
Gregory S
GS
D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D001284:Atrophy; D005145:Face / Q000473:pathology / Q000601:surgery*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D019247:HIV Wasting Syndrome / Q000139:chemically induced / Q000473:pathology; D006801:Humans; D008060:Lipodystrophy / Q000209:etiology* / Q000601:surgery*; D008297:Male; D019736:Prostheses and Implants; D019651:Plastic Surgery Procedures / Q000379:methods*; D012828:Silicones / Q000627:therapeutic use
D012828:Silicones